Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Karyopharm Therapeutics is a commercial-stage oncology company focused on nuclear export inhibition, with its lead product XPOVIO (selinexor) approved for multiple myeloma and diffuse large B-cell lymphoma. The company operates in a highly competitive hematologic malignancy market with limited commercial penetration, facing significant cash burn and balance sheet constraints. Recent stock volatility reflects speculative trading on potential partnership deals or clinical trial readouts rather than fundamental business momentum.
Karyopharm generates revenue through direct commercial sales of XPOVIO in the US oncology market, targeting hematologists and oncologists treating heavily pre-treated blood cancer patients. The company's Selective Inhibitor of Nuclear Export (SINE) mechanism represents a novel approach, but faces intense competition from established therapies (CAR-T, bispecifics, proteasome inhibitors) with superior efficacy profiles. Pricing power is limited by payer pushback on incremental benefit versus standard of care, with gross margins reflecting high manufacturing costs relative to small commercial volumes. The business model requires significant ongoing investment in clinical trials to expand label indications and demonstrate differentiated value, creating negative operating leverage as SG&A and R&D expenses far exceed current revenue base.
Clinical trial data readouts for XPOVIO combination studies in multiple myeloma and potential new indications (endometrial cancer, myelofibrosis)
Quarterly XPOVIO prescription trends and market share data in multiple myeloma versus competing regimens (Darzalex combinations, CAR-T therapies, bispecifics)
Partnership or licensing deal announcements for ex-US territories or combination development programs
Cash runway updates and financing announcements given negative operating cash flow of $100M+ annually
FDA regulatory decisions on label expansion applications or new indication submissions
Competitive displacement risk from superior efficacy therapies in multiple myeloma (CAR-T, bispecifics like Tecvayli/Elrexfio showing deeper responses in earlier lines of therapy)
Regulatory pathway challenges for label expansions given FDA's increasing scrutiny of single-arm trials and accelerated approval conversions in oncology
Reimbursement pressure as payers demand real-world evidence of incremental benefit versus lower-cost alternatives in heavily pre-treated patient populations
Market share erosion in relapsed/refractory multiple myeloma as bispecific antibodies move to earlier treatment lines with better tolerability profiles
Clinical trial failures in combination studies that represent primary growth opportunities (XPOVIO + standard of care regimens)
Inability to differentiate XPOVIO's mechanism of action in crowded oncology market with multiple novel targets under development
Critical liquidity risk with negative $100M annual operating cash flow and limited cash reserves relative to market cap
Potential for highly dilutive equity financing or reverse stock split given sub-$1 stock price and Nasdaq listing requirements
Negative book value and accumulated deficit exceeding $1.5B indicating sustained unprofitability and limited asset base for secured financing
low - Oncology drug demand is largely non-discretionary and driven by disease incidence rather than economic conditions. However, severe recessions could impact hospital budgets, formulary access, and patient out-of-pocket costs for specialty medications. Clinical trial enrollment and physician prescribing patterns show minimal correlation to GDP fluctuations.
Rising interest rates negatively impact valuation multiples for unprofitable biotech companies as the present value of distant future cash flows declines. Higher rates also increase the cost of capital for potential debt financing or convertible offerings needed to fund operations. The company's negative cash flow profile makes it particularly sensitive to risk-free rate changes affecting biotech sector sentiment and access to capital markets.
Moderate - The company's ability to secure additional financing through debt or equity markets is critical given negative operating cash flow. Tightening credit conditions or risk-off sentiment in biotech lending markets could force dilutive equity raises or constrain clinical development programs. Current ratio of 1.12 indicates limited liquidity buffer for operational disruptions.
momentum - The stock attracts speculative biotech traders focused on binary clinical catalysts and partnership rumors rather than fundamental investors. Recent 50-68% short-term gains reflect technical trading and short covering rather than business improvement. The negative cash flow profile, minimal revenue base, and existential financing risk make this unsuitable for value or income investors. High-risk tolerance required given potential for complete capital loss if clinical programs fail or financing becomes unavailable.
high - Micro-cap biotech with limited float, negative fundamentals, and binary clinical catalysts creates extreme volatility. Stock exhibits 100%+ intraday swings around trial readouts or financing announcements. Illiquidity amplifies price movements in both directions, with recent 3-month 50% gain followed by near-flat 1-year performance demonstrating boom-bust pattern typical of distressed biotech names.
